A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
Crohn's Disease Upadacitinib Efficacy Safety Crohn Disease
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics. Authored (or co-authored) 307 research publications.
- accepting new patients
- Start Date
- Completion Date
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- Phase 3
- Study Type
- Last Updated